Lorazepam and driving impairment

Journal of Analytical Toxicology

Volumn 28, Issue 6, 2004, Pages 475-480

  Clarkson, Jayne E ^a   Gordon, Ann Marie ^a   Logan, Barry K ^a  

^a Washington State Patrol   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; BENZODIAZEPINE; CAFFEINE; CARISOPRODOL; CLONAZEPAM; DIAZEPAM; DIPHENHYDRAMINE; FLUNITRAZEPAM; FLURAZEPAM; HYDROCODONE; LORAZEPAM; MEPROBAMATE; METHADONE; MIDAZOLAM; NORDAZEPAM; OXAZEPAM; PROMETHAZINE; TEMAZEPAM; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CONFERENCE PAPER; DISORIENTATION; DIZZINESS; DRIVER; DRIVING ABILITY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MENTAL DISEASE; MUSCLE WEAKNESS; PSYCHOPHARMACOTHERAPY; SEDATION; SIDE EFFECT; TRAFFIC ACCIDENT; TREMOR;

EID: 4344654744     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/28.6.475     Document Type: Conference Paper

References (10)

1. B.A. Way, K.G. Walton, J.W. Koenig, B.J. Eveland, and M.G. Scott. Comparison between the CEDIA and EMIT II immunoassays for the determination of benzodiazepines. Clin. Chim. Acta 271(1): 1-9 (1998).
2. R. Meatherall and A.D. Fraser. Comparison of four immunoassays for the detection of lorazepam in urine. Ther. Drug Monit. 20(6): 673-675 (1998).
3. Physicians' Desk Reference, 56th ed. Medical Economics Data, Montvale NJ, 2002.
4. D.J. Greenblatt, R.T. Schillings, A.A. Kyriakopoulos, R.I. Shader, S.F. Sisenwine, J.A. Knowles, and H.W Ruelius. Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. Clin. Pharmacol. Ther. 20(3): 329-341 (1976).
5. A.A. Kyriakopoulos, DJ. Greenblatt, and R.I. Shader. Clinical pharmacokinetics of lorazepam: a review. J. Clin. Psychiatry 39(10 Pt 2): 16-23 (1978).
6. M. van Laar, E. Volkerts, and M. Verbaten. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psyche/pharmacology (Berl). 154(2): 189-197(2001).
7. J.F. O'Hanlon, A. Vermeeren, M.M. Uiterwijk, L.M. van Veggel, and H.F. Swijgman. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies. Neuropsychobiology 31(2): 81-88(1995).
8. E.R Volkerts, K.A. Brookhuis, and J.F. O'Hanlon. The effects of treatment with buspirone, diazepam and lorazepam on driving performance in real traffic. In Alcohol, Drugs and Traffic Safety - T86, P.C. Noordzij and R. Roszbach, Eds. Excerpta Medica, Amsterdam, The Netherlands, 1986.
9. ROSITA Deliverable D1. Drugs and medicines that are suspected to have a detrimental impact on road user performance. A. Verstraete, Project coordinator. ROSITA 1999
10. Prescribing and dispensing guidelines for medicinal drugs affecting driving performance. ICADTS working group report. J.F. Alvarez and de Gier, co-chairs. ICADTS March 2001.